Research
Hormonal
Muscle-derived musclin (encoded by Ostn) is required for full endurance training adaptation, as its absence impairs training-induced improvements in running performance and mitochondrial activity.
Current evidence for musclin's role in training adaptation comes from short-term mouse studies. While it appears important for performance gains in mice, there is no human data yet. Do not seek out musclin-based interventions for training enhancement until human trials are available.
LimitedSupportsLOW confidence
when exposed to short-term (5 days) treadmill training, all variables described above were significantly lower in Ostn-KO compared to wild-type (WT) animals, indicating impaired training adaptation in musclin deficient mice.
Why this rating
Based on mouse models with short-term interventions; long-term human data is lacking.
Source
The Role of the Skeletal Muscle Secretome in Mediating Endurance and Resistance Training Adaptations
Aurel B. Leuchtmann et al. · Frontiers in Physiology · 2021
DOI 10.3389/fphys.2021.709807
narrative_reviewCited 77×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Skeletal muscle-derived VEGF, induced by endurance exercise via PGC-1α, mediates training-induced capillarization, enhancing oxygen and substrate delivery to muscle tissue.Good
- Endurance training adaptations, including visceral fat reduction and cardiac remodeling, are mediated by muscle-secreted IL-6, as blocking IL-6 receptors impairs these specific structural adaptations without affecting peak endurance capacity (VO2peak).Moderate
- Skeletal muscle-derived myonectin confers protection against ischemia-reperfusion injury in the heart, as endurance training reduces infarct size in wild-type mice but not in myonectin-deficient mice.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →